CeriBell, Inc. CBLL
- Market cap
- $914.2M
- P/E
- 0.0×
Follow CBLL
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 23.00 | 10.01 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 32.75 | 26.83 |
High Price
|
|||
| — | — | — | — | — | — | — | 240 | 281 | 327 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 45 | 65 | 89 |
Revenue
|
|||
| — | — | — | — | — | — | — | 84.38% | 86.72% | 87.89% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (29) | (40) | (53) |
EBT
|
|||
| — | — | — | — | — | — | — | (65.13%) | (61.82%) | (59.97%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (29) | (40) | (53) |
Net Income
|
|||
| — | — | — | — | — | — | — | 1 | 2 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 8.53 | 5.48 | 2.44 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (5.56) | (3.39) | (1.46) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (5.50) | (2.93) | (1.12) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.33) | (0.13) | (0.04) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (5.83) | (3.07) | (1.16) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (21.16) | 16.00 | 4.25 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 5 | 12 | 37 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 2.41 | 4.73 | 9.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 1.62 | 5.16 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 2.50 | 2.05 | 7.43 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (4.47) | (3.67) | (15.64) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | (29) | (35) | (41) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (2) | (2) | (2) |
Capex
|
|||
| — | — | — | — | — | — | — | (31) | (37) | (42) |
FCF
|
|||
| — | — | — | — | — | — | — | 30 | 204 | 168 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 20 | 20 |
Total Debt
|
|||
| — | — | — | — | — | — | — | (34) | (175) | (139) |
Net Debt
|
|||
| — | — | — | — | — | — | — | (112) | 191 | 155 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (28.46%) | (25.36%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | (151.76%) | (229.77%) |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | (102.53%) | (30.83%) |
ROE
|
|||
CeriBell, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LMRI Lumexa Imaging Holdings, Inc. | $949.2M | 0.0× | Compare |
| SIBN SiBone | $830.0M | 0.0× | Compare |
| PRCT PROCEPT BioRobotics Corporation | $1.0B | 0.0× | Compare |
| INMD InMode Ltd. | $815.7M | 11.4× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ENOV Enovis Corporation | $1.1B | 0.0× | Compare |
| TNDM Tandem Diabetes Care, Inc. | $1.1B | 0.0× | Compare |
| VREX VAREX IMAGING | $784.3M | 34.8× | Compare |
| IRMD iRadimed Corporation | $1.1B | 47.1× | Compare |
CeriBell, Inc. (CBLL) key facts
- CeriBell, Inc. (CBLL) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024.
- As of September 25, 2026, CBLL traded at $23.69, a market capitalization of $914.2 million.
- Return on equity was −30.8% and debt-to-equity 0.16.
CeriBell, Inc. (CBLL) Latest News
12 Aug
CeriBell expands EEG platform beyond seizures to target delirium and pediatric applications. Platform expansion into new clinical areas broadens addressable market and supports long-term revenue growth.
11 Aug
CeriBell Inc (CBLL) Q2 2026 revenue accelerated 33% on record results. 33% revenue growth represents solid financial performance that can influence short-term market sentiment without fundamentally altering long-term trajectory.
10 Aug
CeriBell (CBLL) conducted its Q2 2026 earnings call covering financial results, operational updates, and forward outlook. Earnings call content delivers core financial metrics and guidance that typically drive immediate valuation shifts.
CeriBell, Inc. released Q2 2026 earnings call summary covering financial results and outlook. Quarterly earnings call delivers financial metrics and guidance that can shift near-term investor sentiment and valuation.
CeriBell Inc (CBLL) Q2 earnings feature key metrics on revenue, margins and growth that outline quarterly financial results. Q2 earnings metrics supply data on financial performance that can shift near-term investor views on CBLL.
CeriBell Q2 earnings call detailed financial results, operational metrics, and management outlook for the period. Quarterly earnings call supplies performance data and guidance that can moderately shift investor sentiment and near-term valuation.
Ceribell, Inc. reported its second quarter 2026 financial results. Quarterly financial results provide updates on company performance that can affect stock valuation and market perception.
3 Aug
Medicare approved additional payment for CeriBell's delirium monitoring system, leading to share gains. Medicare payment approval directly improves reimbursement for CeriBell's core product.
Ceribell secures CMS New Technology Add-On Payment for its breakthrough point-of-care delirium monitor system. NTAP approval enables higher Medicare reimbursement and accelerates hospital adoption of the core delirium monitoring product.
8 Jun
Ceribell announces publication in Critical Care Medicine reinforcing link between seizure burden measured by Clarity AI algorithm and neurological outcomes. Publication provides clinical validation for Clarity AI that may support adoption and competitive positioning without immediate financial or regulatory effects.
15 May
CeriBell achieves record hospital accounts and usage, signaling early innings of growth. Record hospital accounts and usage demonstrate strong market penetration driving significant revenue growth potential.
12 May
CeriBell Inc (CBLL) Q1 2026 earnings call highlights strong revenue growth and positive market developments. Strong Q1 2026 revenue growth signals significant positive shift in financial performance and market trajectory for CBLL.
CeriBell, Inc. held its Q1 2026 earnings call covering financial results, operational updates, and forward guidance. Quarterly earnings data typically influence short-term valuation and sentiment without guaranteeing long-term structural change.
11 May
CeriBell, Inc. (CBLL) released Q1 earnings call highlights, reporting revenue growth, operational updates, key product developments, and positive forward guidance amid expanding market presence. Q1 earnings highlights detail financial results and guidance that significantly shape investor expectations and stock trajectory.
CeriBell (CBLL) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and management guidance. Q1 2026 earnings transcript reveals financial performance and strategic outlook capable of significantly influencing CBLL's trajectory and investor sentiment.
CeriBell, Inc. (CBLL) reported a Q1 net loss but beat revenue estimates. Revenue beat despite Q1 loss moderately boosts financial outlook and investor sentiment without major trajectory shift.
Ceribell, Inc. (CBLL) reported first quarter 2026 financial results. Quarterly financial results disclosure affects key financial performance metrics and investor sentiment.
7 Mar
CeriBell, Inc. (CBLL) CFO at conference highlights 36% revenue growth and announces EEG platform expansion to pediatrics and delirium. 36% revenue growth and EEG platform expansion into pediatrics and delirium represent major strategic advancements boosting market potential.
CeriBell presented 2026 growth plan at TD Cowen conference, guiding 25%-29% revenue growth, ramping VA contracts, and launching delirium pilot. 25%-29% 2026 growth guidance, VA expansion, and delirium pilot represent major strategic initiatives boosting revenue trajectory and market position.
2 Mar
CeriBell, Inc. (CBLL) posted solid Q4 results, but cautious forward guidance offsets the positivity, according to Canaccord. Solid Q4 performance is balanced by cautious guidance, creating moderate influence on financial outlook and market sentiment.
25 Feb
CeriBell Inc (CBLL) Q4 2025 earnings call highlights revenue surge and market expansion amid ongoing challenges. Revenue surge and market expansion represent major financial gains boosting CBLL's growth trajectory and investor sentiment.
24 Feb
CeriBell, Inc. (CBLL) released Q4 earnings call highlights detailing financial performance, operational updates, and future outlook. Q4 earnings call highlights cover financial results, guidance, and strategic developments poised to significantly shape investor sentiment and company trajectory.
CeriBell, Inc. (CBLL) Q4 2025 earnings call summary covers financial results, operational updates, and forward-looking guidance for the neurotechnology firm. Q4 earnings summary delivers key financial metrics, revenue growth, and strategic outlook directly shaping investor expectations and stock trajectory.
CeriBell (CBLL) Q4 2025 earnings call transcript released, covering financial results, operational highlights, and management guidance. Q4 earnings transcripts disclose financial outcomes and strategic outlook, significantly shaping investor expectations and market valuation.
Ceribell, Inc. (CBLL) reported fourth quarter and full year 2025 financial results. Quarterly and annual financial results disclosure significantly affects investor sentiment, valuation, and market performance.
CeriBell, Inc. (CBLL) reported a Q4 net loss but surpassed revenue estimates. Q4 loss despite revenue beat signals mixed financial results with moderate effects on performance and sentiment.
14 Jan
CeriBell, Inc. (CBLL) outlined its growth strategy for 2026 at the JPMorgan MedTech conference, focusing on expanding its EEG technology for delirium and stroke management. The company aims to enhance its product offerings and market presence in these critical areas, signaling a commitment to innovation and addressing significant healthcare needs. The expansion into delirium and stroke EEG technology represents a major strategic move that could significantly alter CeriBell's market positioning and investor sentiment.
6 Jan
CeriBell, Inc. (CBLL) has received FDA Breakthrough Device Designation for its AI-based technology aimed at detecting large vessel occlusion (LVO) strokes. This designation is intended to expedite the development and review process for medical devices that offer significant advantages over existing options. The approval highlights the potential of CeriBell's innovative approach to improve patient outcomes in stroke care. FDA Breakthrough Device Designation can significantly enhance CeriBell's market position and accelerate product development.
5 Jan
Ceribell, Inc. has received FDA Breakthrough Device Designation for its innovative solution aimed at detecting and monitoring large vessel occlusion (LVO) strokes. This designation is expected to expedite the development and review process, potentially enhancing patient outcomes in emergency settings. The technology aims to improve the speed and accuracy of stroke diagnosis, which is critical for timely treatment. FDA Breakthrough Device Designation can significantly enhance product development timelines and market positioning.
30 Dec
Ceribell, Inc. (CBLL) will participate in the 44th Annual J.P. Morgan Healthcare Conference, a significant event for healthcare companies to showcase their innovations and strategies to investors. This participation highlights Ceribell's commitment to engaging with the investment community and potentially attracting interest in its products and services. Participation in a major healthcare conference can enhance visibility and investor interest, impacting market sentiment and potential financial performance.